Phase 1/2 trial of AXO-AAV-GM1 (AAV9-GLB1) gene therapy for infantile- and juvenile-onset GM1 gangliosidosis

被引：0

作者：

Tifft, Cynthia ^{[1
]}

D'Souza, Precilla ^{[1
]}

Johnston, Jean M. ^{[1
]}

Acosta, Maria T. ^{[1
]}

Nicoli, Elena-Raluca ^{[1
]}

Rothermel, Caroline ^{[1
]}

Thurm, Audrey ^{[2
]}

Karunakara, Ajith ^{[3
]}

Thorp, Benjamin ^{[3
]}

Ross, Peter ^{[3
]}

Jameson, John ^{[3
]}

Sheehan, Michael ^{[3
]}

Vaughn, Toby ^{[3
]}

Valencia, Donna ^{[3
]}

De Boever, Erika ^{[3
]}

Corcoran, Gavin ^{[3
]}

机构：

[1] Nat Human Genome Res Inst, Bethesda, MD USA

[2] Nat Inst Mental Hlth, Bethesda, MD USA

[3] Sio Gene Therapies Inc, New York, NY USA

来源：

MOLECULAR GENETICS AND METABOLISM | 2022年 / 135卷 / 02期

关键词：

D O I：

10.1016/j.ymgme.2021.11.317

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

302

引用

页码：S119 / S119

页数：1

共 50 条

[21] Developement of an Ex Vivo Gene Therapy for Infantile GM1 Gangliosidosis
Bucciarelli, Linda
Fabris, Camilla
Milazzo, Rita
Biffi, Alessandra
Poletti, Valentina
MOLECULAR THERAPY, 2023, 31 (04) : 38 - 39
[22] Investigational AAV Gene Therapy LYS-GM101 for GM1-Gangliosidosis
Hocquemiller, Michael
Olivier, Sophie
Parker, Samantha
Aiach, Karen
Laufer, Ralph
MOLECULAR THERAPY, 2020, 28 (04) : 562 - 563
[23] GENE-THERAPY IN GM1 GANGLIOSIDOSIS
SEO, HC
JOHNSON, PA
PYRCE, D
MASADA, RI
KISHIMOTO, Y
OBRIEN, JS
FASEB JOURNAL, 1994, 8 (07): : A1440 - A1440
[24] Effects of AAV Serotype on Treatment of Feline GM1 Gangliosidosis by Cerebrospinal Fluid Delivery of AAV
Garrett, Courtney J.
Gross, Amanda
Gray-Edwards, Heather L.
Hocquemiller, Michael
Sena-Esteves, Miguel
Martin, Douglas R.
MOLECULAR THERAPY, 2022, 30 (04) : 121 - 121
[25] Gene Therapy for GM1 Gangliosidosis Mediated by AAV Vector Carrying BBB-Penetrable Enzyme
Matsushima, Saki
Iizuka, Sayoko
Kinoshita, Masafumi
Takagi, Haruna
Iizuka, Shunsuke
Ohtsuki, Kota
Imakiire, Atsushi
Nagashima, Takashi
Okamoto, Shinichiro
Higuchi, Takashi
Shimada, Yohta
Hioki, Hiroyuki
Sonoda, Hiroyuki
Watabe, Ayako M.
Ohashi, Toya
Kobayashi, Hiroshi
MOLECULAR THERAPY, 2023, 31 (04) : 635 - 636
[26] BBB Disruption Enhances the Efficacy of Systemic AAV9 Gene Delivery in GM1 Gangliosidosis Mice
Batista, Ana Rita
Reardon, Christopher P.
Todeasa, Sophia H.
Sena-Esteves, Miguel
MOLECULAR THERAPY, 2018, 26 (05) : 406 - 406
[27] Development of a Hematopoietic Stem Cell Gene Therapy for Infantile GM1 Gangliosidosis
Bucciarelli, Linda
Fabris, Camilla
Scarabello, Elena
Accardo, Massimo
Poletti, Valentina
Biffi, Alessandra
MOLECULAR THERAPY, 2024, 32 (04) : 733 - 734
[28] Identification of a novel pseudodeficiency allele in the GLB1 gene in a carrier of GM1 gangliosidosis
Gort, L.
Santamaria, R.
Grinberg, D.
Vilageliu, L.
Chabas, A.
CLINICAL GENETICS, 2007, 72 (02) : 109 - 111
[29] Comparing Efficacy of AAV Capsid Serotypes for the Treatment of Feline GM1 Gangliosidosis
Garrett, Courtney
Gross, Amanda L.
Gray-Edwards, Heather L.
Sena-Esteves, Miguel
Martin, Douglas R.
MOLECULAR THERAPY, 2024, 32 (04) : 525 - 525
[30] Effect of Administration Route and AAV Serotype for Treatment of Feline GM1 Gangliosidosis
Gross, Amanda L.
Gray-Edwards, Heather
Sena-Esteves, Miguel
Martin, Douglas R.
MOLECULAR THERAPY, 2020, 28 (04) : 217 - 218

← 1 2 3 4 5 →